This may provide insight into the co-administration of IL-10 with anti-TNF-α agents in the treatment of inflammatory infectious diseases like colitis and IBD toward enhanced therapeutic outcomes, with reduced inflammation and improved tissue healing. This evidence concerns the gene IL10 and inflammatory bowel disease.